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Background: Traumatic brain injury is a leading cause of death and disability worldwide. Laboratory and clinical studies
demonstrate a possible beneficial effect of erythropoietin in improving outcomes in the traumatic brain injury cohort.
However, there are concerns regarding the association of erythropoietin and thrombosis in the critically ill. A large-scale,
multi-centre, blinded, parallel-group, placebo-controlled, randomised trial is currently underway to address this hypothesis.
Methods/design: The erythropoietin in traumatic brain injury trial is a stratified prospective, multi-centre, randomised,
blinded, parallel-group, placebo-controlled phase III trial. It aims to determine whether the administration of erythropoietin
compared to placebo improves neurological outcome in patients with moderate or severe traumatic brain injury at six
months after injury. The trial is designed to recruit 606 patients between 15 and 65 years of age with severe (Glasgow
Coma Score: 3 to 8) or moderate (Glasgow Coma Score: 9 to 12) traumatic brain injury in Australia, New Zealand,
Kingdom of Saudi Arabia, France, Finland, Germany and Ireland.
Trial patients will receive either subcutaneous erythropoietin or placebo within 24 hours of injury, and weekly
thereafter for up to three doses during the intensive care unit admission. The primary outcome will be the
combined proportion of unfavourable neurological outcomes at six months: severe disability or death. Secondary
outcomes will include the rate of proximal deep venous thrombosis detected by compression Doppler ultrasound,
six-month mortality, the proportion of patients with composite vascular events (deep venous thrombosis, pulmonary
embolism, myocardial infarction, cardiac arrest and cerebrovascular events) at six months and quality of life with health
economic evaluations.
Discussion: When completed, the trial aims to provide evidence on the efficacy and safety of erythropoietin in
traumatic brain injury patients, and to provide clear guidance for clinicians in their management of this devastating
condition.
Trial registration: Australian New Zealand Clinical Trials registry: ACTRN12609000827235 (registered on 22 September
2009).
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Traumatic brain injury (TBI) is a devastating condition
which affects close to 1,000 people each year in
Australia, causes extensive long-term disability and suf-
fering, which subsequently results in approximately 1
billion Australian dollars in lifetimes costs per year [1].
Disability follows from primary and secondary brain in-
jury. Attenuation of secondary brain injury (decreasing the
additional injury due to the inflammatory, excitotoxic and
apoptotic response to trauma) is possible [2]. Erythropoietin
(EPO) is a glycoprotein hormone with pleiotropic cytokine-
like effects [3]. EPO has effects, independent of those on
erythropoiesis, which are relevant to patients who have
had a TBI. They include anti-apoptotic activity and protect-
ive neurological effects in the presence of hypoxia and is-
chaemia [2-4]. A neuroprotective effect of EPO has been
demonstrated in animal models of TBI [5,6]. A large,
multi-centre, randomised controlled trial (RCT) demon-
strated that EPO improved survival in a retrospectively
identified trauma cohort [7]. A subsequent large RCT by
the same group found that while EPO did not reduce
transfusion rates, in a prospectively identified trauma co-
hort (including TBI) EPO significantly decreased 29-day
mortality compared to a placebo (3.5 versus 6.6%) [8].
Additional observational studies and one very small RCT
support the hypothesis that EPO may improve neurological
outcomes after TBI [9,10]. However, many concerns have
been raised about the ability of EPO to increase the risk of
venous thromboembolism (VTE) [8,11,12]. The United
States Food and Drug Administration recently added a
black box warning regarding this risk on EPO preparations.
However, it is worth noting that the largest trial in the crit-
ically ill to date demonstrates a clear survival advantage in
traumatically injured patients who are generally most vul-
nerable to VTE complications.
The question of whether the administration of EPO
benefits patients with TBI remains unanswered. To ad-
dress this evidence gap we are undertaking a large
multi-centre, blinded, parallel-group, placebo-controlled
randomised trial comparing the administration of EPO
with a placebo. This trial will be sufficiently powered to
detect clinically relevant differences in neurological out-
comes measured by the eight-level Extended Glasgow
Outcome Scale (GOSE) [13] at six months following
injury.
Methods/design
Trial design and outcomes
The erythropoietin in traumatic brain injury (EPO-TBI)
trial is a stratified prospective, multi-centre, randomised,
blinded, parallel-group, placebo-controlled phase III trial.
It aims to determine whether the administration of EPO
compared to a placebo improves neurological outcome in
patients with moderate or severe TBI at six months afterinjury. The trial is designed to recruit 606 patients be-
tween 15 and 65 years of age with severe (Glasgow Coma
Score(GCS): 3 to 8) or moderate (GCS: 9 to 12) TBI in
Australia, New Zealand, Kingdom of Saudi Arabia, France,
Finland, Germany and Ireland.
Participants
Patients aged between 15 and 65 years with non-penetrating
moderate or severe TBI will be eligible for this trial. These
criteria were designed to exclude patients with unsurvivable
neurological injury, patients at a high risk of VTE and those
who would be exposed to additional risk due to the trial
drug.
Inclusion criteria
Patients with non-penetrating moderate (Glasgow Coma
Score (GCS) 9–12) or severe (GCS 3–8) traumatic brain
injury admitted to an ICU who:
1. Are ≥15 to ≤65 years of agea
2. Are <24 hours since primary traumatic injury
3. Are expected to stay ≥48 hours
4. Have a haemoglobin not exceeding the upper limit
of the applicable normal reference range in clinical
use at the treating institutionb
5. Have written informed consent from legal surrogate
Exclusion criteria
Patients are excluded from the study if any of the follow-
ing criteria applyc:
1. GCS = 3 and fixed dilated pupils
2. History of deep vein thrombosis, pulmonary
embolism or other thromboembolic event
3. A chronic hypercoagulable disorder, including
known malignancy
4. Treatment with erythropoietin in the last 30 days
5. First dose of study drug unable to be given within
24 hours of primary injury
6. Pregnancy or lactation or 3 months post-partum
7. Uncontrolled hypertension (systolic blood pressure
>200 mmHg or diastolic blood pressure >110
mmHg)
8. Acute myocardial infarct within the past 12 months
9. Past history of epilepsy with seizures in past 3
months
10. Expected to die imminently (<24 hours)
11. Inability to perform lower limb ultrasounds
12. Known sensitivity to mammalian cell-derived
products
13. Hypersensitivity to the active substance or to any of
the additives
14. Pure red cell aplasia
15. End-stage renal failure (receives chronic dialysis)
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or severe co-morbidity that may interfere with
the assessment of outcome
17. Spinal cord injury
18. Treatment with any investigational drug within 30
days before enrolment
19. The treating physician believes it is not in the best
interests of the patient to be randomised to this trial
Outcomes measures
The primary outcome of this trial is the patients’ neuro-
logical status at six months, summarized as a binary
midpoint reduction of their eight-level Extended Glasgow
Outcome Scale (GOSE) score, defined as favourable (GOSE
score: 5 to 8; moderate disability and good recovery) or un-
favourable (GOSE score: 1 to 4; death and severe disability).
Secondary outcomes include:
1. Neurological status at six months summarized by
the eight-level GOSE
2. Quality of life assessment using the Short Form 12
(SF-12) [14] and EuroQoL-5D (EQ-5D) [15] at six
months
3. Mortality at six months
4. Proximal deep venous thrombosis (DVT) detected
by ultrasound
5. Occurrence of a thrombotic vascular event (including
DVT, pulmonary embolism, myocardial infarction, cardiac
arrest and cerebrovascular events) at six months. The
definitions for these events are previously reported [16]
6. Resource use and costs at six months
7. Incremental cost effectivenessScreen in ICU EPO EPO
Randomise 
ICU index admission
< 24 hours administraon
Day 1 Day 8
Doppler US* Doppler US Doppler U
*The baseline ultrasound may be performed before or 
EPO = Epoetin alfa 40,000 IU or placebo
US = Ultrasound
Figure 1 Summary of trial treatment and follow up schedule. The bas
after the first dose administration. EPO, Erythropoietin (Epoetin alfa) 40,000Trial interventions
The intervention to be examined in this trial is the sub-
cutaneous administration of erythropoietin 40,000 Inter-
national Units (IU) compared to a placebo (0.9% saline).
A summary of the trial interventions and follow up
schedule is provided in Figure 1.
Investigational product
The trial drug is Epoetin alfa 40,000 IU in a pre-filled
syringe, manufactured by Janssen-Cilag Pty Ltd, or the
placebo sodium chloride 0.9. The trial drug will be ad-
ministered by subcutaneous injection.
For patients randomised to the treatment arm, an un-
blinded nurse will administer the full contents of the
Epoetin alfa 40,000 IU pre-filled syringe to the patient. For
patients randomised to the placebo arm, an unblinded
nurse will administer 1 mL from a sodium chloride 0.9%
10 mL ampoule.
The first dose will be given within 24 hours of the esti-
mated time of TBI, and then weekly for up to two more
doses (on trial days eight and 15). The trial drug will
only be administered to patients during the ICU admis-
sion. If the patient is discharged to the general ward (be-
fore trial day eight or before day 15) they will not receive
any further doses of trial drug. Patients readmitted to ICU
during the same hospital stay will not receive any further
doses of the trial drug.
Variable haemoglobin threshold for dosing to reduce the
risk of thromboembolic complications
Previous trials examining the long-term use of EPO in renal
failure [12] and cancer [11] patients targeting haemoglobinEPO
6 month follow up
Day 15
S Doppler US
at least within 48 hours after the first dose administration.
eline ultrasound may be performed before or at least within 48 hours
IU or normal saline placebo; US, Ultrasound.
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strated an increased risk of thromboembolic complications.
Observational studies also demonstrate that the Hb con-
centration in critically ill patients falls rapidly in the first 72
hours of admission [17,18]. A dosing structure based on
Hb concentration was developed to address the known risks
of thromboembolic complications associated with EPO use:
the first dose of trial drug is administered only if the haemo-
globin (Hb) concentration is less than the upper limit of the
applicable normal reference range in clinical use at the treat-
ing institution; the second and third doses are administered
only if the Hb concentration is <120 g/L (12 g/dL).
The second (trial day eight) and third (trial day 15)
doses may be given the day before or after dosing day,
so the trial drug is prepared in pharmacy business hours.
The weekly dose will not be administered if the patient’s
pre-medication Hb is ≥120 g/L (12 g/dL); the trial drug
will be temporarily withheld for that dose. The patient
will be assessed on the next scheduled dosing day. If
their Hb is <120 g/L (12 g/dL), the dose may be given if
the patient is still in the ICU and has not met the per-
manent withholding criteria.
At Johannes Gutenberg-Universtität, Mainz Germany
an additional temporary trial drug withholding criterion
applies. The weekly dose will not be administered if the
patient has a refractory high blood pressure; the trial
drug will be withheld for that dose, and the patient will
be assessed on the next scheduled dosing day. No fur-
ther doses will be administered if the patient has met
any permanent withholding criteria.
Permanent withholding criteria:
1. Development of proximal deep venous thrombosis
2. Development of pulmonary embolism
3. Any other thrombotic event
4. Acute myocardial infarction
5. Cardiac arrest or ventricular fibrillation
6. Cerebrovascular accident
7. Any serious adverse event or protocol deviation
where, in the attending physician’s opinion, the
patient should not receive any further doses of the
trial drug
8. Consent has been withdrawn or consent to continue
has not been granted
Management of traumatic brain injury
The ICU medical team will have full independent control
of patient management, however the trial management
committee request that standardised TBI clinical practice
follows Brain Trauma Foundation [19] guidelines.
Compression Doppler ultrasound
Critically ill patients are at risk of VTE complications. Pre-
vious studies, which did not specifically screen for VTE,have demonstrated an association of EPO with increased
rates of VTE. The true risk is unknown in the critically ill
as clinical examination has severe limitations, and many
clinically undetected VTE complications are revealed
when prospective screening is performed. The risk of VTE
in the traumatically injured patients is potentially further
elevated, as concerns regarding intracerebral haemorrhage
frequently discourage clinicians giving pharmaceutical
agents (low molecular weight heparins) to mitigate this
risk. Therefore, to address this potential and largely un-
known risk of EPO in the traumatically injured patients,
we designed a prospective VTE screening algorithm. Bilat-
eral compression Doppler ultrasound of the lower extrem-
ities will be performed to monitor for proximal DVT at
baseline (before the first dose if possible, or at least within
48 hours after the first dose administration) then twice
weekly after each dose of the trial drug for three weeks or
up to ICU discharge, whichever occurs first. The procedure
for the ultrasound was standardised, with evaluation of the
following veins: common femoral, proximal femoral, mid
femoral, distal femoral, popliteal and trifurcation.
Up to six scheduled twice weekly ultrasounds will be
performed if the patient is an inpatient in the ICU for lon-
ger than three weeks. No further scheduled twice weekly
ultrasounds are required beyond trial day 21.
If the patient meets a temporary or permanent with-
holding criteria and remains in the ICU, the twice weekly
compression Doppler ultrasounds are performed up to
trial day 21 or ICU discharge, whichever occurs first.
Bilateral compression Doppler ultrasounds will be per-
formed on the general ward if the patient has been trans-
ferred after a dose of the trial drug and before a scheduled
ultrasound has been performed. This will ensure at least
one bilateral compression Doppler ultrasound will be per-
formed after each dose of the trial drug.
The site treating clinicians outside the ICU (known
variously by names such as Parent Unit, Admitting Unit
or Attending Medical Service) are required to notify the
site researchers of any occurrences of VTE as soon as it
is diagnosed.
Additional bilateral compression Doppler ultrasounds
will be performed on suspicion of DVT or pulmonary
embolism. The treating clinician may therefore take add-
itional measures to reduce the risk of complications from
any identified thrombosis. We anticipate that this algo-
rithm will mitigate any additional risk that could be posed
by the use of EPO in this cohort.
Randomisation and allocation concealment
Concealed randomisation will be performed via a web-
based system that includes block randomisation at each
site. Treatment allocation will be stratified by site and
also by the severity of TBI at randomisation (moderate
(GCS: 9 to 12) or severe (GCS: 3 to 8).
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by the use of a robust primary outcome minimally sus-
ceptible to ascertainment bias, and by blinded assess-
ment of the primary outcome by a trained outcome
assessor at the coordinating centre (Australia and New
Zealand) or by trained, blinded outcome assessors in
each country in Europe and the Kingdom of Saudi Arabia.
Blinding plan
Site personnel will be blinded to treatment allocation.
For the efficient conduct of the trial the site pharmacists,
site unblinded dosing nurses and the pharmacists at the
central pharmacy in France (Clinical Trial Department of
the Pharmaceutical Establishment of Assistance Publique-
Hôpitaux de Paris) will be unblinded to treatment
assignment.
Staff at the coordinating centre will be blinded to
treatment allocation, except for an unblinded project of-
ficer (Appendix 1) and designee, the analyst program-
mers responsible for the web-based data management
system and a nominated statistician who will supervise
data extraction from the database for interim and final
analyses. The French management team will be blinded
to treatment assignment.
Following patient randomisation by the site investiga-
tor or designee, an unblinded trial pharmacist will dis-
pense the trial drug in a tamperproof sealed opaque box
(Figure 2) to blind the treatment assignment. The box
may only be opened by the site’s designated unblinded
trial dosing nurse. For patients who receive the active
treatment the sealed box will consist of one Epoetin alfa
40,000 IU pre-filled syringe labelled with direction for
use ‘Inject 1 ml subcutaneously over at least 1 minute’.
For patients who receive the placebo the sealed box will
consist of one sodium chloride 0.9% 10 mL ampoule la-
belled with direction for use ‘Inject 1 ml subcutaneously
over at least 1 minute’.Figure 2 Blinded tamperproof sealed box.For safety reasons, unblinded dosing nurses will be al-
located in each research site to administer EPO or pla-
cebo doses discreetly, with a screen around the patient
bed area. The trial drug or placebo dose may be checked
with a second unblinded nurse if required to comply
with local hospital regulations. After dose administration
the unblinded dosing nurse will discard the used trial
drug in such a manner as to maintain the blind. These
unblinded dosing nurses will have access to the un-
blinded trial pharmacist. Unblinded dosing nurses will
not be involved in the care of a trial patient and may not
discuss trial drug treatment with research staff or other
members of the ICU or hospital staff.
Data collection and management
All data will be collected by trained staff at each trial site
using a paper source document developed by the coord-
inating centre. Data will then be entered into a web
database designed by the trial project manager in collab-
oration with the Monash University Monash University
Clinical Informatics and Data Management Unit. Data
queries will be automatically generated via the elec-
tronic data collection database, and at monitoring by
the trial project manager or the clinical research associ-
ate (in France).
Randomised patients will be followed up to death or
six months post-randomisation (whichever occurs first).
Data collection will be restricted primarily to those vari-
ables necessary to define clinical patient characteristics
including: baseline demographics, primary diagnoses,
physiological parameters, Acute Physiology and Chronic
Health Evaluation II (APACHE II), Injury Severity Score
(ISS), Abbreviated Injury Severity Score (AIS) and Com-
puted Tomography Brain Marshall Score [20], diagnostic
interventions, therapeutic interventions, and documenta-
tion of deaths and other serious adverse events (SAE).
To prepare for the six-month follow-up assessment,
patients and/or their legal surrogate will be asked to
provide three possible points of contact (home and close
family contact details) to the research staff prior to hos-
pital discharge. Full protocol data will be collected in all
patients including those excluded at any stage. Patients
who are alive at six months after randomisation (or their
carer or proxy if more appropriate) will be interviewed
by a trained outcome assessor from Monash University
for patients in Australia and New Zealand, or trained
outcome assessors in each country in Europe and the
Kingdom of Saudi Arabia. The regional assessors will
use a standardized structured telephone questionnaire
[21] to measure the eight-level GOSE [13]. Neurological
outcomes will then be defined as favourable (GOSE
score: 5 to 8; moderate disability and good recovery) or
unfavourable (GOSE score: 1 to 4; death and severe dis-
ability). Patients subsequently withdrawn for any reason
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brovascular accident, cardiac arrest, or an SAE) or who did
not receive the trial drug will be followed up on, according
to the study follow-up schedule, and analysed according to
the modified intention-to-treat principle [22,23].
Trained outcome assessors (Appendix 2) will collect
data for surviving patients at six months for quality of
life assessment using the EQ-5D [15] questionnaire and
the SF-12 [14] questionnaire. If the patient is not well
enough or not available to complete the questionnaires,
the SF-12 questionnaire will not be completed [24,25]
and quality of life will not be assessed for that patient.
Data will be collected from surviving patients at six
months for cost effectiveness analysis, with utilities calcu-
lated using the EQ-5D [15] results, and costs will be calcu-
lated based on ICU, acute and post-acute care resource
use. If the patient is not well enough or not available to
complete the EQ-5D the patient’s proxy will be asked to
complete it for the patient.
The outcome assessments will be monitored by an ex-
perienced and trained outcome assessor at Monash
University.
Ethical issues
This is a trial conducted in patients who are uncon-
scious and unable to consent to participation, therefore
the patient’s legal surrogate will be approached to pro-
vide consent for the patient. Patients who recover suffi-
cient cognition to understand the explanation of the trial
will additionally be asked to consent to continue in the
trial if this is required under the ethics committee ap-
proval conditions.
In France patients may be enrolled under an Emergency
clause. Informed consent was obtained from each patient’s
legal surrogate for participation in the trial.
Approval for this protocol has been obtained from ap-
propriate regulatory authorities, and from participating
hospitals’ human research ethics committees. The list of
responsible ethics committees is provided as an Additional
file 1.
Sample size and power
The estimated rate of unfavourable neurological out-
come (death and severe disability) in Australian and
New Zealand patients with moderate and severe TBI
[26,27] is approximately 50%.
A trial of 574 patients will have a 90% power at an
alpha of 0.05 to detect a 14% absolute risk reduction (50
versus 36%) and 80% power to detect a 12% (50 versus
38%) absolute risk reduction in unfavourable neuro-
logical outcome. A trial of this size was also estimated to
have 80% power to detect a 9% absolute risk increase in
proximal lower limb DVT from an assumed baseline
proportion of 18% (50% increase in relative risk) at aone-sided alpha of 0.05. Allowing for a 5% withdrawal
and loss to follow-up rate, we will recruit 606 patients to
prevent any loss of power and to conduct an adequately
powered modified intention-to-treat analysis [22,23].
Statistical analysis
Independent senior statisticians at Monash University
Department of Epidemiology and Preventive Medicine
will perform data analyses following a detailed statistical
analysis plan, which will be published separately in the
journal Trials.
A modified intention-to-treat analysis will be per-
formed based on all randomly assigned patients, except
those withdrawing consent for use of all trial data, those
not fulfilling inclusion criteria and those who never re-
ceive the intervention [22,23]. Baseline variables will be
summarised using descriptive statistics. The trial primary
outcome will be compared between treatments with an
unadjusted risk ratio and 95% confidence interval. Sensi-
tivity analyses will be performed using logistic regression
adjusting for stratification factors, pre-specified prognos-
tic factors and any other baseline covariates exhibiting
substantial imbalance between randomisation arms. Fur-
thermore, a proportional odds cumulative logit model
[28,29], adjusting for relevant covariates, will be applied
to the eight-level vector of the six-month GOSE score.
Other secondary analyses, including assessment of
outcomes according to actual treatment received, quality
of life assessment, mortality at hospital discharge and six
months and incidence of adverse events (AE), will be
compared between treatment groups using unadjusted
and adjusted logistic regression and log-binomial regres-
sion. Pre-specified subgroup analyses will be obtained
using interaction terms in logistic regression models.
Adjusted effect estimates of the EPO intervention, de-
rived from logistic and proportional odds ordinal logistic
models, will be reported as adjusted risk ratios averaged
over the remaining covariates, as recently recommended
[30-32]. Time-to-event analyses will be undertaken using
Kaplan-Meier curves, as well as unadjusted and adjusted
Cox proportional hazards regression models.
Data and safety monitoring
An independent Data Safety and Monitoring Committee
(DSMC) comprising of experts in clinical trials, biostat-
istics and intensive care, will monitor SAEs throughout
the trial, and pre-defined outcomes at designated interim
analyses.
Given the potential for EPO to increase the risk of VTE,
there are two planned interim safety analyses scheduled by
the DSMC at six months, following 33% (n = 202) and
66% (n = 404) patient recruitment. The Haybittle-Peto criter-
ion (|Zk| > =3) for early stopping were applied at these first
and second analyses. The final analyses at full recruitment
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value |Z3| > =1.975 rather than 1.960) [33].
Consistent with other studies in critically ill patients,
AEs already defined and reported as study outcomes
(apart from death) will not be reported a second time as
SAEs [34].Discussion
TBI is a common and devastating condition with few
proven specific therapies available. The administration of
EPO has the potential to reduce neurological damage
and improve outcome, and is supported by a scientific
rationale and laboratory data. The EPO-TBI design aims
to maximise the ability to detect a beneficial effect, if
one exists, between EPO and improved neurological
function after TBI. Furthermore, our design features also
aim to minimise the risk of VTE in this population, and
to develop a prospective screening plan which will read-
ily identify VTE events if they occur, allowing clinicians
to provide appropriate treatment rapidly. EPO-TBI aims
to provide definitive guidance for clinicians regarding
the true efficacy and safety of EPO in the management
of TBI.Trial status
The trial commenced in May 2010 at The Alfred Hospital,
Melbourne Australia. Two interim analyses were con-
ducted with approval by the DSMC to continue the trial
without alteration to the protocol. The target recruitment
of 606 patients was achieved on 1 November 2014, mak-
ing final six-month outcomes available by May 2015.Endnotes
aSix sites have a minimum age of 15 years, 13 sites
have a minimum age of 16 years and 10 sites have a
minimum age of 18 years.
b<140 g/L at Johannes Gutenberg-Universtität, Mainz
Germany, <148 g/L for males and <135 g/L for females
at Royal Adelaide Hospital, Adelaide Australia.
cAdditional exclusion criteria at Johannes Gutenberg-
Universtität, Mainz Germany. Uncontrolled hypertension
parameters were more stringent (systolic blood pressure
of >160 mm Hg or diastolic blood pressure of >90 mm
Hg), morbid obesity, coronary artery disease, peripheral
arterial occlusive disease, vascular disease of the carotid
arteries, cerebrovascular disorders, recent stroke, con-
traindications against prophylaxis of DVT or an in-
creased risk for DVT (for example, with additional
trauma and /or operations, severe varicose veins, severe
smokers, intake of oral contraceptives, infections and
inflammation).Appendix 1: EPO-TBI unblinded project officer
Belinda Howe, Australian and New Zealand Intensive
Care Research Centre, Monash University, Melbourne,
Australia.
Appendix 2: EPO-TBI outcome assessors
Heather Waddy, Australian and New Zealand Intensive
Care Research Centre, Monash University, Melbourne,
Australia.
Marwan Al Kishi, Department of Medicine, King
Abdulaziz Medical City, Riyadh, Kingdom of Saudi
Arabia.
Sarah Kambire, Unité de Recherche Clinique Lariboisière-
Saint Louis, Assistance Publique-Hôpitaux de Paris, France.
Serge Camelo, Unité de Recherche Clinique Lariboisière-
Saint Louis, Assistance Publique-Hôpitaux de Paris, France.
Markus Skrifvars, Intensive Care Unit, Department of
Anaesthesiology and Intensive Care Medicine, Helsinki
University Hospital, Helsinki, Finland.
Stepani Bendel, Intensive Care Unit, Division of Anaes-
thesiology and Intensive Care Medicine, Kuopio University
Hospital, Kuopio, Finland.
Carole Schilling, Royal College of Surgeons in Ireland,
Education and Research Centre, Beaumont Hospital,
Dublin, Ireland.
Thomas Kerz, Department of Neurosurgery, Intensive
Care Therapy Unit, Universitätsmedizin, Mainz, Germany.
Lynnette Murray, Australian and New Zealand Intensive
Care Research Centre, Monash University, Melbourne,
Australia.
Appendix 3: EPO-TBI management committee
Rinaldo Bellomo, Department of Intensive Care, Austin
Health, Melbourne, Australia.
Alistair Nichol, Department of Anaesthesia and Intensive
Care Medicine, St Vincent’s University Hospital, Dublin,
Ireland.
Craig French, Department of Intensive Care, Western
Health, Melbourne, Australia.
D James Cooper, Department of Intensive Care Medicine,
The Alfred, Melbourne, Australia.
Olivier Huet, Intensive Care Unit, Department of
Anesthesiology and Intensive Care Medicine, Centre
Hospitalier Universitaire La Cavale Blanche, Brest, France.
Lorraine Little, Australian and New Zealand Intensive
Care Research Centre, Monash University, Melbourne,
Australia.
Anne Mak, Pharmacy Department, The Alfred, Melbourne,
Australia.
Ville Pettilä, Intensive care Units, Division of Anaes-
thesiology and Intensive Care Medicine, Helsinki University
Central Hospital, Helsinki, Finland.
Jeffrey Presneill, Department of Intensive Care, Mater
Health Services, Brisbane, Australia.
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The Alfred, Melbourne, Australia.
Dinesh Varma, Department of Radiology, The Alfred,
Melbourne, Australia.
Judy Wills, Department of Radiology, The Alfred,
Melbourne, Australia.Appendix 4: EPO-TBI sites, principal investigator
and research coordinator/s
Auckland City Hospital, New Zealand: Colin McArthur,
Yan Chen, Lynette Newby.
Beaumont Hospital, Ireland: Criona Walshe, James
O’Rourke, Carole Schilling.
Canberra Hospital, Australia: Imogen Mitchell, Frank
Van Haren, Helen Rodgers. Marta Kot
Christchurch Hospital, New Zealand: Seton Henderson,
Jan Mehrtens, Sascha Noble.
Dunedin Hospital, New Zealand: Matthew Bailey,
Robyn Hutchinson, Dawn France.
Gold Coast University Hospital, Australia: Brent
Richards, Mandy Tallott.
Helsinki University Central Hospital, Finland: Markus
Skrifvars, Heikki Vartiala, Marianne Eliasson.
Hôpital Caremeau, France: Jean Yves Lefrant, Laurent
Muller, Claire Roger, Christian Bengler, Pierre Barbaste.
Hôpital Charles Nicolle, France: Benoit Veber, Marie
Gilles-Baray, Pierre-Gildas Guitard, Helene Braud.
Hôpital de Bicêtre, France: Jacques Duranteau, Anatole
Harrois, Samy Figueiredo, Sophie Hamada.
Hôpital Lariboisière, France: Didier Payen, Anne Claire
Lukaszewicz, Charles Damoisel, Sarah Kambire.
Hôpital Michallon, France: Jean François Payen, Pauline
Manhes, Gilles Franconey, Perrine Boucheix.
Johannes Gutenberg-Universtität, Germany: Thomas
Kerz.
John Hunter Hospital, Australia: Peter Harrigan, Miranda
Hardie.
King Abdulaziz Medical City, Kingdom of Saudi Arabia:
Samir Haddad, Yaseen Arabi, Marwan Al Kishi, Ahmad
Deeb, Shmeylan Al Harbi, Lolowa Al-Swaidan ,Turki Al
Moammar, Juliet Lingling, Shella Caliwag, Hanie Richi.
Kuopio University Hospital, Finland: Stepani Bendel,
Sari Rahikainen, Mikko Myllymaki.
Liverpool Hospital, Australia: Victor Tam, Sharon
Micallef.
Nepean Hospital, Australia: Louise Cole, Leonie
Weisbrodt.
Royal Adelaide Hospital, Australia: Richard Strickland,
Justine Rivett, Sonya Kloeden, Stephanie O’Connor.
Royal Hobart Hospital, Australia: David Cooper, Richard
McAllister.
Royal Melbourne Hospital, Australia: Nerina Harley,
Deborah Barge, Elizabeth Moore, Andrea Jordan.Royal North Shore Hospital, Australia: Simon Finfer,
Elizabeth Yarad, Simon Bird, Anne O’Connor.
Royal Perth Hospital, Australia: Geoffrey Dobb, Jenny
Chamberlain, Michelle Barr, Elizabeth Jenkinson.
Royal Prince Alfred Hospital, Australia: David Gattas,
Heidi Buhr, Debra Hutch, Megan Keir.
St Vincent’s Hospital Sydney, Australia: Priya Nair,
Claire Reynolds, Serena Knowles.
The Alfred, Australia: D. James Cooper, Jasmin Board,
Shirley Vallance, Phoebe McCracken.
The Townsville Hospital, Australia: Geoffrey Gordon,
Stephen Reeves.
Wellington Regional Hospital, New Zealand: Richard
Dinsdale, Lynn Andrews, Dianne Mackle, Sally Hurford.
Westmead Hospital, Australia: Vineet Nayyar, Christina
Whitehead, Jing Kong.
Appendix 5: EPO-TBI French management team
Jacques Duranteau, National Principal Investigator, Service
d’Anesthésie-Réanimation, Hôpitaux universitaires Paris
Sud, Assistance Publique des Hôpitaux de Paris, Hôpital
de Bicêtre, Le Kremlin-Bicêtre, France.
Eric Vicaut, Unité de Recherche Clinique Lariboisière-
Saint Louis, Assistance Publique-Hôpitaux de Paris,
France.
Philippe Gallula, Pole Promotion International, Assist-
ance Publique-Hôpitaux de Paris, France.
Vidhya Raghavan, Unité de Recherche Clinique
Lariboisière-Saint Louis, Assistance Publique-Hôpitaux
de Paris, France.
Amel Chamam, Unité de Recherche Clinique Lariboi-
sière-Saint Louis, Assistance Publique-Hôpitaux de
Paris, France.
Sarah Kambire, Unité de Recherche Clinique Lariboisière-
Saint Louis, Assistance Publique-Hôpitaux de Paris, France.
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